Mednet Logo
Community

Do you consider adding a brachytherapy boost to IMRT in patients with cT3b and/or cN1 prostate cancer?

ASCENDE-RT excluded these patients as well as those with a PSA > 40, but it seems these patients may stand to benefit as well.
1 Answer
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on

For T3b disease we do consider a brachy boost.

We look at MRI imaging and based on extent of involvement which usually is to proximal part, and if it appears we can implant that area to full dose, we consider a brachy boost.

Join for free or sign in to see the full answer